Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26932602 |
US |
41 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 102 | 26932607 |
US |
35 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 103 | 26932609 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 104 | 26932615 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AZELASTINE HYDROCHLORIDE, AZELASTINE, BACLOFEN, CETIRIZINE HCL, CETIRIZINE, DOXAZOSIN MESYLATE, EZETIMIBE, FAMOTIDINE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, PREGABALIN, NIMODIPINE, ONDANSETRON HYDROCHLORIDE, OXCARBAZEPINE, QUETIAPINE FUMARATE, QUETIAPINE, TIOTROPIUM BROMIDE INHALATION SPRAY, TEMAZEPAM, ERGOCALCIFEROL, WARFARIN SODIUM, WARFARIN, ZOLPIDEM TARTRATE, |
||||
| 105 | 26932627 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 106 | 26932680 |
US |
45 | 1 |
Accidental exposure to product, Exposure via skin contact, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 107 | 26932690 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 108 | 26932695 |
US |
36 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 109 | 26932697 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 110 | 26932709 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 111 | 26932710 |
US |
57 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 112 | 26932789 |
US |
10 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 113 | 26932799 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 114 | 26933229 |
US |
45 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 115 | 26933294 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 116 | 26933297 |
US |
75 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 117 | 26933306 |
US |
35 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 118 | 26933367 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 119 | 26933409 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 120 | 26933417 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 121 | 26933449 |
US |
10 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 122 | 26933458 |
US |
46 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 123 | 26933477 |
US |
14 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 124 | 26933496 |
US |
2 | |
Eczema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, |
||||
| 125 | 26933518 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 126 | 26933533 |
US |
82 | 1 |
Nasal polyps, Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 127 | 26933536 |
US |
37 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 128 | 26933568 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 129 | 26933604 |
US |
28 | 2 |
Accidental exposure to product, Injection site pain, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 130 | 26933609 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 131 | 26933611 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 132 | 26933616 |
US |
15 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 133 | 26933621 |
US |
81 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 134 | 26933657 |
US |
17 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 135 | 26933825 |
US |
23 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 136 | 26933861 |
US |
75 | 2 |
Unevaluable event, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 137 | 26933885 |
US |
71 | 2 |
Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 138 | 26933984 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 139 | 26933999 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 140 | 26926648 |
US |
2 | |
Injection site bruising, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 141 | 26926658 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, LORATADINE, LORATADINE ORAL, ERGOCALCIFEROL, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 142 | 26927094 |
US |
7 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 143 | 26927482 |
US |
73 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 144 | 26927497 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 145 | 26927504 |
US |
37 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 146 | 26927687 |
US |
2 | |
Coronary artery bypass, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 147 | 26927723 |
US |
62 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 148 | 26927747 |
US |
53 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 149 | 26928423 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 150 | 26928430 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 151 | 26928838 |
US |
57 | 2 |
Asthma, Heart rate increased, Anxiety, Nerve injury, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 152 | 26929098 |
US |
68 | 2 |
Peripheral swelling, Device use issue, Accidental exposure to product, Exposure via skin contact, Injury associated with device, |
||||
EVOLOCUMAB, |
||||
| 153 | 26929327 |
US |
46 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 154 | 26929898 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 155 | 26930292 |
US |
73 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 156 | 26930384 |
US |
38 | 2 |
Injection site vesicles, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, BIOTIN, SERTRALINE HYDROCHLORIDE, LEVOTHYROXINE SODIUM, TIRZEPATIDE, |
||||
| 157 | 26930737 |
US |
68 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 158 | 26930749 |
CN |
46 | 2 |
Xerophthalmia, Pityriasis rosea, Injection site pain, Arthralgia, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 159 | 26921606 |
US |
80 | 2 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Device use error, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 160 | 26921700 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 161 | 26921906 |
US |
1 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Product preparation issue, |
||||
DUPILUMAB, |
||||
| 162 | 26921928 |
US |
68 | 1 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, Injection site pain, |
||||
DUPILUMAB, |
||||
| 163 | 26922152 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
DUPILUMAB, |
||||
| 164 | 26922165 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 165 | 26922323 |
US |
55 | 2 |
Drug dose omission by device, Accidental exposure to product, Exposure via skin contact, Injection site pain, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 166 | 26922432 |
US |
59 | 1 |
Back pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 167 | 26922449 |
US |
18 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 168 | 26922450 |
US |
2 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 169 | 26922793 |
US |
12 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 170 | 26923052 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 171 | 26923063 |
US |
22 | 2 |
Loss of consciousness, Head injury, Accidental exposure to product, Exposure via skin contact, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 172 | 26923067 |
US |
12 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 173 | 26923090 |
US |
63 | 2 |
Exposure via skin contact, Product dose omission issue, Accidental exposure to product, Product storage issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 174 | 26923099 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 175 | 26923238 |
US |
75 | 2 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 176 | 26923504 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 177 | 26923759 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 178 | 26923768 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 179 | 26924040 |
US |
64 | 1 |
Exposure via skin contact, Accidental exposure to product, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 180 | 26924064 |
CA |
75 | |
Tooth extraction, Product leakage, Injection site pain, Injection site haemorrhage, Incorrect dose administered, Accidental exposure to product, Exposure via skin contact, Intentional dose omission, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 181 | 26925090 |
US |
56 | 2 |
Device difficult to use, Accidental exposure to product, Drug dose omission by device, Device use error, Pain in extremity, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 182 | 26925685 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 183 | 26926223 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 184 | 26926396 |
US |
91 | 2 |
Drug dose omission by device, Device difficult to use, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 185 | 26926548 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 186 | 26926606 |
US |
65 | 2 |
Exposure via skin contact, Accidental exposure to product, Chest pain, |
||||
EVOLOCUMAB, |
||||
| 187 | 26914659 |
US |
73 | 1 |
Device difficult to use, Drug dose omission by device, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 188 | 26914750 |
US |
2 | |
Injection site pain, Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 189 | 26914828 |
US |
72 | 2 |
Accidental exposure to product, Exposure via skin contact, Product dispensing issue, |
||||
INSULIN GLARGINE, |
||||
| 190 | 26915019 |
US |
||
Device delivery system issue, Drug dose omission by device, Exposure via skin contact, Device delivery system issue, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 191 | 26915057 |
US |
2 | |
Device deployment issue, Accidental exposure to product, Exposure via skin contact, |
||||
GOLIMUMAB, |
||||
| 192 | 26915276 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 193 | 26915423 |
US |
64 | 2 |
Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 194 | 26915624 |
US |
67 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 195 | 26915625 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 196 | 26915680 |
59 | ||
Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, Device leakage, Device delivery system issue, |
||||
| 197 | 26915683 |
47 | ||
Exposure via skin contact, Incorrect dose administered, Accidental exposure to product, Device leakage, |
||||
| 198 | 26915739 |
US |
38 | 2 |
Incorrect dose administered by device, Device difficult to use, Accidental exposure to product, Exposure via skin contact, Product communication issue, |
||||
EVOLOCUMAB, |
||||
| 199 | 26915800 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 200 | 26915827 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, Product administration error, Drug dose omission by device, |
||||
DENOSUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30